Clinical Trial Update: Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating fluorescein for sentinel lymph node biopsy in breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fluorescein (fluorescein sodium)

Snippet

Sponsor: University of Utah | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN